BR112019027257A2 - método para reduzir inflamação de pulmão - Google Patents

método para reduzir inflamação de pulmão Download PDF

Info

Publication number
BR112019027257A2
BR112019027257A2 BR112019027257-7A BR112019027257A BR112019027257A2 BR 112019027257 A2 BR112019027257 A2 BR 112019027257A2 BR 112019027257 A BR112019027257 A BR 112019027257A BR 112019027257 A2 BR112019027257 A2 BR 112019027257A2
Authority
BR
Brazil
Prior art keywords
chelating agent
dose
day
inflammation
lung
Prior art date
Application number
BR112019027257-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Barry Clements
Original Assignee
Respirion Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902365A external-priority patent/AU2017902365A0/en
Application filed by Respirion Pharmaceuticals Pty Ltd filed Critical Respirion Pharmaceuticals Pty Ltd
Publication of BR112019027257A2 publication Critical patent/BR112019027257A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019027257-7A 2017-06-20 2018-06-20 método para reduzir inflamação de pulmão BR112019027257A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902365 2017-06-20
AU2017902365A AU2017902365A0 (en) 2017-06-20 Method For Reducing Lung Inflammation
PCT/AU2018/050609 WO2018232452A1 (en) 2017-06-20 2018-06-20 METHOD FOR REDUCING PULMONARY INFLAMMATION

Publications (1)

Publication Number Publication Date
BR112019027257A2 true BR112019027257A2 (pt) 2020-07-14

Family

ID=64735378

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019027257-7A BR112019027257A2 (pt) 2017-06-20 2018-06-20 método para reduzir inflamação de pulmão

Country Status (8)

Country Link
US (2) US11491126B2 (https=)
EP (1) EP3641749A4 (https=)
JP (3) JP7729713B2 (https=)
CN (1) CN111050762A (https=)
AU (2) AU2018286649B2 (https=)
BR (1) BR112019027257A2 (https=)
CA (1) CA3067857A1 (https=)
WO (1) WO2018232452A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI818601B (zh) * 2021-10-29 2023-10-11 原創生醫股份有限公司 用於上呼吸道給藥之組成物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
AU2016228976B2 (en) * 2015-03-11 2018-11-08 University Of Cincinnati Compositions and methods for treating bacterial infection
EP3383415B1 (en) * 2015-12-01 2021-03-31 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
AU2023270302A1 (en) 2023-12-14
EP3641749A4 (en) 2021-03-17
AU2023270302B2 (en) 2025-10-23
AU2018286649B2 (en) 2023-11-09
US20200163920A1 (en) 2020-05-28
CA3067857A1 (en) 2018-12-27
JP2025098035A (ja) 2025-07-01
JP2020524173A (ja) 2020-08-13
JP2023071952A (ja) 2023-05-23
JP7729713B2 (ja) 2025-08-26
WO2018232452A1 (en) 2018-12-27
JP7848150B2 (ja) 2026-04-20
AU2018286649A1 (en) 2019-12-05
US11491126B2 (en) 2022-11-08
EP3641749A1 (en) 2020-04-29
US20230045633A1 (en) 2023-02-09
CN111050762A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
Cantin et al. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection
Wenzler et al. Inhaled antibiotics for gram-negative respiratory infections
Sermet-Gaudelus et al. Nebulized antibiotics in cystic fibrosis
AU2023285900B2 (en) Method For Reducing Lung Infection
US20190231686A1 (en) Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces
Wasik et al. Salt Therapy as a Complementary Method for the Treatment of Respiratory Tract Diseases, With a Focus on Mold-Related Illness.
NZ564110A (en) Formulations for alteration of biophysical properties of mucosal lining
JP2025098035A (ja) 肺炎症を低減させる方法
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
Garcia-Contreras et al. Aerosol treatment of cystic fibrosis
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão
Hasan et al. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics
AU2011227613B2 (en) Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
Narasimhan et al. New and investigational treatments in cystic fibrosis
Spencer et al. Newer therapies for cystic fibrosis
US20170020838A1 (en) Treatment for respiratory disease
WO2023230057A1 (en) Therapeutic useful against antimicrobial resistant agents
JP2004533417A (ja) 上皮／基質間付着力の増強により改善される喘息、嚢胞性線維症、およびインフルエンザなどの疾病の治療におけるプロピオン酸フルチカゾンの使用
Fila et al. 73 Influence of treatment with sildenafil on lung function and exercise tolerance in cystic fibrosis adults
Bragonzi et al. WS7. 1 Pre-clinical evaluation of novel antibiotic POL7001 against Pseudomonas aeruginosa in lung infection models

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025016291-4 PROTOCOLO 870250067787 EM 01/08/2025 19:14.

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]